Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM001 for RSV Prevention in Infants
NCT06083623Phase 3Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of TNM001 in respiratory syncytial virus infection (RSV), sponsored by Trinomab Pharmaceutical. Primary endpoint: Incidence of medically attended lower respiratory tract infection due to RT-PCR confirmed RSV at 150 days. Started Sep 2023; status: completed.
02
Drugs
TNM001
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06083623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083623.